A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.,International Journal of Clinical Oncology

当前位置： X-MOL 学术 › Int. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
International Journal of Clinical Oncology ( IF 3.3 ) Pub Date : 2019-12-10 , DOI: 10.1007/s10147-019-01589-6
Nobuaki Matsubara ₁ , Go Kimura ₂ , Hiroji Uemura ₃ , Hirotsugu Uemura ₄ , Motonobu Nakamura ₅ , Satoshi Nagamori ₆ , Atsushi Mizokami ₇ , Hiroaki Kikukawa ₈ , Makoto Hosono ₉ , Seigo Kinuya ₉ , Heiko Krissel ₁₀ , Jonathan Siegel ₁₁ , Yoshiyuki Kakehi ₁₂

Affiliation

Division of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Department of Urology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan.
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama, Japan.
Department of Urology, Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, Japan.
Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan.
Department of Urology, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4 Jo, Shiroishi-ku, Sapporo, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa, Japan.
Department of Urology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, Japan.
The Japanese Society of Nuclear Medicine, 2-28-45, Honkomagome, Bunkyo-ku, Tokyo, Japan.
Clinical Development, SBU Oncology, Bayer AG, Berlin, Germany.
Clinical Statistics, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
Kagawa University, Takamatsu, Kagawa, Japan.

ERA 223 compared concurrent abiraterone acetate/prednisolone (AAP) plus radium-223 with AAP plus placebo in men with chemotherapy-naïve asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. We report data from a subgroup of Japanese patients in ERA 223.

中文翻译：

镭223和安慰剂联合醋酸阿比特龙和泼尼松龙在去势抵抗性转移性前列腺癌中的随机，双盲比较：ERA 223研究中日本患者的亚组分析。

ERA 223比较了无化疗或无症状轻度转移性去势抵抗性前列腺癌（mCRPC）和骨转移的男性患者中并发的醋酸阿比特龙/泼尼松龙（AAP）加镭223和AAP加安慰剂的比较。我们报告了ERA 223中来自日本患者亚组的数据。

更新日期：2020-01-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>